Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA) therapy Leqvio (inclisiran) for its use in lowering low-density lipoprotein cholesterol (bad cholesterol or LDL-C). Leqvio FDA approval is for the drug to be administered in two doses a year, after an initial dose followed by another […]
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (alpha-1 liver disease). As part of the alliance, Alnylam Pharmaceuticals’ ALN-AAT02 and Dicerna Pharmaceuticals’ DCR-A1AT, both investigational RNAi therapeutics will be evaluated in alpha-1 liver disease. Both the RNAi […]